Serina Therapeutics, Inc. (SER)
NYSEAMERICAN: SER · Real-Time Price · USD
2.780
+0.110 (4.12%)
Aug 11, 2026, 4:00 PM EDT - Market closed
Serina Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 24.53 | 3.06 | 3.67 | 7.62 | 0.65 | 0.58 |
Cash & Short-Term Investments | 24.53 | 3.06 | 3.67 | 7.62 | 0.65 | 0.58 |
Cash Growth | 474.78% | -16.78% | -51.80% | 1081.24% | 10.45% | 10.82% |
Accounts Receivable | - | - | - | - | 0 | 0.03 |
Other Current Assets | 1.95 | 3.02 | 2 | - | 1.8 | 1.63 |
Total Current Assets | 26.47 | 6.08 | 5.68 | 7.62 | 2.45 | 2.23 |
Net Property, Plant & Equipment | 0.8 | 0.84 | 1.05 | 1.35 | - | - |
Other Intangible Assets | - | - | - | - | 0.74 | 0.87 |
Other Long-Term Assets | 0.03 | 0.03 | - | - | 0.05 | 0.05 |
Total Assets | 27.3 | 6.95 | 6.72 | 8.97 | 3.24 | 3.15 |
Accounts Payable | 2.83 | 1.93 | 0.74 | 0.58 | 1.03 | 0.77 |
Accrued Expenses | 1.51 | 1.21 | 1.43 | 0.58 | - | - |
Current Portion of Long-Term Debt | - | - | - | - | 7.65 | 7.14 |
Other Current Liabilities | 2 | 0.43 | 0.19 | 0.25 | 1.4 | 1.06 |
Total Current Liabilities | 6.34 | 3.56 | 2.37 | 1.41 | 10.08 | 8.97 |
Long-Term Debt | 3.01 | 2.95 | - | 2.98 | 10.48 | 6.06 |
Long-Term Leases | 0.16 | 0.2 | 0.27 | 0.46 | - | - |
Other Long-Term Liabilities | 0.16 | 0.28 | 3.58 | - | - | - |
Total Long-Term Liabilities | 3.33 | 3.43 | 3.85 | 3.45 | 10.48 | 6.06 |
Total Liabilities | 9.67 | 6.99 | 6.22 | 4.86 | 20.56 | 15.03 |
Preferred Stock | 4.94 | 4.94 | - | - | - | - |
Common Stock | 0 | 0 | 0 | - | - | 0 |
Additional Paid-in Capital | 83.09 | 58.54 | 44.96 | 0.88 | 99 | 93.91 |
Accumulated Other Comprehensive Income | -0.01 | -0.01 | - | - | - | - |
Retained Earnings | -70.4 | -63.5 | -44.32 | -33.18 | -116.21 | -105.75 |
Total Common Shareholders' Equity | 17.63 | -0.04 | 0.64 | -32.29 | -17.21 | -11.83 |
Minority Interest | - | - | -0.13 | 36.4 | -0.1 | -0.04 |
Shareholders' Equity | 17.63 | -0.04 | 0.51 | -32.29 | -34.53 | -11.88 |
Total Liabilities & Equity | 27.3 | 6.95 | 6.72 | 8.97 | 3.24 | 3.15 |
Total Debt | 3.17 | 3.14 | 0.27 | 3.45 | 18.12 | 13.2 |
Net Cash (Debt) | 21.36 | -0.09 | 3.4 | 4.17 | -17.48 | -12.62 |
Net Cash Growth | 428.64% | - | -18.45% | - | - | - |
Net Cash Per Share | 1.98 | -0.01 | 0.46 | 0.57 | -8.15 | -11.71 |
Book Value | 17.63 | -0.04 | 0.64 | -32.29 | -17.21 | -11.83 |
Book Value Per Share | 1.64 | -0.00 | 0.09 | -4.39 | -8.02 | -10.98 |
Tangible Book Value | 17.63 | -0.04 | 0.64 | -32.29 | -17.95 | -12.7 |
Tangible Book Value Per Share | 1.64 | -0.00 | 0.09 | -4.39 | -8.37 | -11.79 |